CSPC Pharmaceutical Group stock
Price history
−0.26% over the period1 year: from $7.73 (November 18, 2025) to $7.71 (November 18, 2026), −0.26%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 18, 2026 | $7.71 |
| October 30, 2026 | $7.86 |
| September 30, 2026 | $10.07 |
| August 31, 2026 | $9.24 |
| July 31, 2026 | $8.58 |
| June 30, 2026 | $6.97 |
| May 29, 2026 | $7.50 |
| April 30, 2026 | $8.41 |
| March 31, 2026 | $9.10 |
| February 27, 2026 | $9.90 |
| January 30, 2026 | $9.60 |
| December 31, 2025 | $8.44 |
| November 28, 2025 | $7.91 |
| November 18, 2025 | $7.73 |
At a glance
The company
Manufactures and sells a wide range of pharmaceutical products including branded drugs, bulk pharmaceutical products, and functional foods, primarily in China and internationally
Latest results
Quarter to June 30, 2026 · EPS ¥0.46 (estimate ¥0.16)
Next event
TickerLandia's take on CSPC Pharmaceutical Group
- Cheaper than similar companies: trailing 12-month P/E 11 vs 19 (−43%) in a group of 10.
- Strong point: Financial strength (90/100 in its group). Weak point: Market momentum (46/100).
- “Best dividend stocks” (Hong Kong): No. 5 of 22.
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−29.65% from the 52-week high
Analysts · 24 analysts
Average target$12.67+64.37% vs. price
Buy 21 · Hold 1 · Sell 2 · Buy
TickerLandia Fingerprint: CSPC Pharmaceutical Group
Compared with similar companies: very high financial strength.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,069 Asia-Pacific stocks.
Pricelow22
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 10.8 2 Price/book 2.04 27 Price/sales 2.87 42 Forward P/E 11.8 27 EV/EBITDA 7.50 10 Profitabilityaverage52
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 71.9% 34 Net margin 23.7% 78 Operating margin 27.9% 42 ROE 20.9% 48 ROA 10.7% 58 Earnings stabilityhigh66
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 3.1% 78 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthhigh66
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +93.80% 98 Average revenue growth (3 years) −5.62% 6 Earnings growth (year over year) +388.40% 94 Financial strengthvery high90
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength · more cash than debt −1.13 98 Interest coverage 102.6 90 Debt/equitycounts in reverse: lower means more financial strength 0.02 94 Current ratio 2.14 78 Dividendaverage59
How much it returns to shareholders, and for how long.
Metric Value Position in group Payout ratio 69.9% 69 Consecutive dividend years 14 years 20 Dividend yield 4.6% 90 Market momentumaverage46
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −5.07% 35 Relative strength (6 months) +11.09% 69 1-year return −0.26% 43 Distance from 200-day average −11.05% 37 Riskhigh63
How much the price swings.
Metric Value Position in group Volatility (60 days) 39.7% 57 Beta (1 year) 1.21 74 Maximum drawdown (12 months) 37.8% 58
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
CSPC Pharmaceutical Group is cheaper than similar companies
CSPC Pharmaceutical Group's P/E (trailing 12 months): 10.8, −43% against the median of a group of 10 similar companies (18.9).
Compared with 10 similar companies
| Metric | CSPC Pharmaceutical Group | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 10.8 | Low | |
| Forward P/E | 11.8 | Low | |
| Operating margin | 27.9% | Middle | |
| ROE | 20.9% | Middle | |
| Debt/equity | 0.02 | Low |
Grey band: the middle half of the group; tick: the median; dot: CSPC Pharmaceutical Group. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
¥12.13B
Latest quarter · Q2 2026
Net income
¥5.23B
Latest quarter · Q2 2026
Quarterly net margin
43.2%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $89.99B
- P/E
- 10.8
- EPS
- $0.73
- Volume
- 71.58M
- Daily trading
- €81.14M
- Dividend yield
- 6.61%
- Last ex-dividend on October 20, 2026
How CSPC Pharmaceutical Group is changing
All resultsRevenue grew 0.8% a year on average over the last 5 years
Operating margin fell from 21.8% to 15.2%
Free cash flow equal to 64% of net income
Returns
CSPC Pharmaceutical Group returns with dividends
$1,000 invested in CSPC Pharmaceutical Group 5 years ago, on November 18, 2021, would be worth $1,137 today with dividends reinvested: +13.68% in total, +2.60% per year. On price alone it would be $928 (−7.22%).
| Period | CSPC Pharmaceutical Group | Hang Seng | $1,000 becomes |
|---|---|---|---|
| 1 month | −13.57% | −1.51% | $864 |
| 6 months | +1.72% | −8.44% | $1,017 |
| Year to date | −8.65% | −8.28% | $914 |
| 1 year | +6.06% | −9.34% | $1,061 |
| 3 years | +26.08% | +32.23% | $1,261 |
| 5 years | +13.68% | −7.15% | $1,137 |
| 10 years | +144.32% | +5.21% | $2,443 |
Over the last 6 months it has done better than 40% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. Hang Seng: price only. Calculate your investment
The chart in detail
CSPC Pharmaceutical Group: technical analysis
CSPC Pharmaceutical Group shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 43.2% below its all-time closing high ($13.57, May 28, 2018).
- Trend
- No clear trend
- RSI (14 sessions)
- 34
- Between 30 and 70
- vs 200-session average
- −11.05%
Support and resistance
Price areas where CSPC Pharmaceutical Group has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$8.63+11.96%4 touches, last on November 5, 2026
- Resistance$8.34+8.17%4 touches, last on August 6, 2026
- Resistance$7.98+3.50%3 touches, last on June 1, 2026
- Last price$7.71
- Support$7.59−1.62%2 touches, last on November 2, 2026
- Support$7.21−6.55%2 touches, last on December 16, 2025
- Support$6.57−14.83%3 touches, last on June 25, 2026
Volatility and risk
Over the last year it has moved more than the Hang Seng.
- Beta (1 year) vs Hang Seng
- 1.21
- Volatility (60 sessions, annualised)
- 39.7%
- Largest fall in the last year
- −37.79%
In session, November 18, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
CSPC Pharmaceutical Group: seasonality
Average monthly price change over 33 years
Over the last 33 years, the strongest month for CSPC Pharmaceutical Group has been February: +9.54% on average, positive in 24 years out of 32. The weakest has been December: −1.18% on average, positive in 16 years out of 32. November, the current month, has been positive in 15 years out of 32 (+0.69% on average).
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.93% | +2.65% | 17 of 32 |
| February | +9.54% | +5.32% | 24 of 32 |
| March | +1.54% | −0.93% | 15 of 32 |
| April | +5.90% | +2.85% | 19 of 32 |
| May | +3.15% | +2.35% | 18 of 32 |
| June | −0.67% | −3.40% | 9 of 32 |
| July | +1.58% | 0.00% | 13 of 33 |
| August | +1.16% | 0.00% | 15 of 33 |
| September | +0.11% | +0.25% | 17 of 33 |
| October | +0.18% | +1.80% | 18 of 33 |
| November | +0.69% | −0.35% | 15 of 32 |
| December | −1.18% | +0.05% | 16 of 32 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
CSPC Pharmaceutical Group and its competitors
CSPC Pharmaceutical Group serves patients and healthcare providers in Mainland China, other Asian regions, Europe, North America and other international markets, manufacturing and selling finished drugs, bulk products and functional food items. Its portfolio covers stroke, memory impairment, Parkinson's disease, cancer and chemotherapy-related infection support, antibiotics, hypertension, diabetes, osteoporosis, arthritis and pain relief, as well as active pharmaceutical ingredients such as antibiotics, vitamin C and caffeine.
- Headquarters
- Shijiazhuang, China
- Employees
- 18,626
- Founded
- 1992
- Chief executive
- Lei Cai
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| CSPC Pharmaceutical Group1093 | $11.47B | 27.9% | 10.8 | +1.72% |
| Astellas Pharma4503 | $30.89B | 23.5% | 12.8 | +18.37% |
| Daiichi Sankyo4568 | $32.83B | 12.6% | 18.8 | +5.65% |
| Otsuka Holdings4578 | $41.01B | 18.0% | 17.0 | +9.88% |
| Chugai Pharmaceutical4519 | $76.25B | 48.3% | 24.1 | −7.89% |
| RecordatiREC | $12.09B | 32.6% | 21.1 | +2.62% |
Same industry or related industries, similar size. Compare CSPC Pharmaceutical Group with its competitors · Full profile
More on CSPC Pharmaceutical Group
- CSPC Pharmaceutical Group revenue and financials
- CSPC Pharmaceutical Group dividend and valuation
- CSPC Pharmaceutical Group stock return
- CSPC Pharmaceutical Group employees, headquarters and business
